Andrew S Wulfman ESQ LLC

KEI Letter to HHS Secretary Azar (3/18/2018), highlights potential forfeiture of patent rights due to failure to disclose NIH funding of research leading to the discovery and development of new drug therapies in patent applications pursuant to 35 U.S.C. 202(c)(1). (Subject patent is for Gilead’s Sofosbuvir). https://www.keionline.org//HHS-Azar-KEI-Patent-7964580-SOF

Recent Federal Circuit decision in patent infringement case. Exmark Manufacturing Company v. Briggs & Stratton Power Products, http://caselaw.findlaw.com/us-federal-circuit/1885894.html

A cogent discussion of the implications of the criminal conviction in the Sinoval trade secret theft case. https://www.duanemorris.com//three_lessons_sinovel_trade_s

Important discussion on the issue of privilege in internal investigations. https://www.bakermckenzie.com//privilege-in-internal-inves The Bilta decision of the English High Court is also discussed here: https://m.mayerbrown.com//FDR_The-scope-of-privilege-in-in... But see discussion of the U.S. rule on privilege in internal investigations discussed here: https://www.skadden.com//preserving-attorney-client-privil

Prescient overview of global and domestic political and economic trends affecting the business environment for 2018. https://www.skadden.com///2018-insights/10-themes-for-2018